What is the treatment for Valsalva (Valsalva maneuver) retinopathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Valsalva Retinopathy

For Valsalva retinopathy, observation is the first-line treatment for most cases, with surgical intervention (pars plana vitrectomy) reserved for cases with dense hemorrhage that doesn't resolve spontaneously or when rapid visual recovery is needed.

Understanding Valsalva Retinopathy

Valsalva retinopathy is a condition characterized by sudden, painless loss of vision due to hemorrhage in various retinal compartments following a Valsalva maneuver, which involves increased intrathoracic pressure against a closed glottis.

Common causes include:

  • Lifting heavy objects (34.4%)
  • Vomiting (20.6%)
  • Straining (20.6%)
  • Coughing (17.2%) 1

The hemorrhage typically occurs in the:

  • Subhyaloid space (42.3%)
  • Intraretinal space (32.7%)
  • Intravitreal space (23.1%)
  • Subretinal space (13.4%) 1

Treatment Algorithm

First-Line: Observation

  • Indicated for: Small to moderate hemorrhages
  • Duration: Typically 3-4 months
  • Expected outcome: Mean time to clearance is approximately 99 days 1
  • Visual prognosis: Generally excellent with final visual acuity of 20/22 at 1 year 1

Second-Line: Nd:YAG Laser Membranotomy

  • Indicated for: Premacular hemorrhages with sufficient depth
  • Mechanism: Creates an opening in the posterior hyaloid membrane to drain blood into the vitreous for faster absorption
  • Limitations: May be ineffective for coagulated blood 2, 3

Third-Line: Pars Plana Vitrectomy

  • Indicated for:
    • Dense hemorrhages that don't resolve spontaneously
    • Cases requiring rapid visual recovery
    • Failed Nd:YAG laser treatment
    • Coagulated blood
  • Technique: 20G, 23G, or smaller gauge vitrectomy
  • Outcome: Mean time to clearance is approximately 4.5 days 1
  • Visual prognosis: Excellent with final visual acuity of 1.0 in most cases 2

Special Considerations

Underlying Conditions

  • Always evaluate for underlying retinal pathology that may have predisposed to hemorrhage
  • In patients with inflammatory conditions like pars-planitis, Valsalva retinopathy may complicate management 4

Prevention

  • Advise patients with known eye conditions that predispose to vitreal hemorrhages to avoid Valsalva maneuvers 4
  • Activities to avoid include:
    • Heavy weightlifting
    • Vigorous physical exertion
    • Activities that dramatically increase blood pressure

Warning Signs

  • Subretinal hemorrhage (rather than preretinal) may indicate underlying pathology such as polypoidal choroidal vasculopathy requiring different management 5

Monitoring

  • Follow-up examinations should be scheduled at:
    • 1 month after initial presentation
    • 3 months (expected visual acuity: 20/59)
    • 6 months (expected visual acuity: 20/48)
    • 1 year (expected visual acuity: 20/22) 1

Pitfalls to Avoid

  • Don't assume all hemorrhages will resolve spontaneously; dense hemorrhages may require intervention
  • Don't miss underlying retinal pathology that may have been unmasked by the Valsalva event
  • Avoid Nd:YAG laser when the blood is coagulated as it will likely be ineffective 2
  • Don't delay vitrectomy when indicated, as earlier intervention leads to faster visual recovery

The treatment approach should be guided by the size, location, and duration of the hemorrhage, with the goal of optimizing visual outcomes while minimizing procedural risks.

References

Research

Long-term evolution of Valsalva retinopathy: a case series.

Journal of medical case reports, 2012

Research

Treatment of Valsalva retinopathy.

Optometry and vision science : official publication of the American Academy of Optometry, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.